PREVELANCE OF OVARIAN CANCER AND ITS CORELATION WITH AGE IN PAKISTAN

Full Article - PDF

Published: 2021-12-24

Page: 462-466


MUHAMMAD WAQAR MAZHAR *

Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan.

SAIRA SAIF

Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan.

AHMAD RAZA

Department of Biological sciences, Nuclear Institute for Agriculture & Biology, Faisalabad, Pakistan.

ASMA TAJ

Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan.

SOHAIL WARIS

Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan.

ABDUL MANAN

Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan.

MUHAMMAD IRFAN

Department of Bioinformatics and Biotechnology, Government College University, Faisalabad, Pakistan.

HIRA TAHIR

University of Health Sciences, Lahore, Pakistan.

FATIMA MAZHAR

Muhammad Nawaz Sharif University of Agriculture, Multan, Pakistan.

*Author to whom correspondence should be addressed.


Abstract

Introduction: group of diseases that is originated from the different parts of ovaries and cause production of abnormal cells that divide uncontrolled themselves in the ovaries is known as ovarian cancer. OC is mainly classified into majorly three types on the base of three components of ovaries known as epithelium, stroma and germinal cells. Approximately, 7000 women develop OC and 4200 of them die every year in UK. In Pakistan the incidence of OC is increasing at the rate of around 13.6%. Approximately 70% cases are diagnosed at later stages.

Methodology: The blood sample was collected by Layyah region. The CA125 identification through Elisa technique for their better identification on the basis of antibodies. Normal values of CA125 were considered less than 35 U/ml. the other tumor marker was also measured such as fibrinogen, prolactin, CA15.3, PT, APTT, INR, D Dimer, and CA19.9.

Results: The mean age of patients was 59.0 ± 8.1while the minimum and maximum age at which the tumor marker detection was 22 and 74 years. The no of patient was found in order of 25 >24 > 10 in 1st, 2nd and 3rd age groups, respectively. The clinical histopathological test in the ovarian cancer patients show that the tumor size 5.21 ± 3.42, fibrinogen 5.09 ± 1.29, CA-199 (U/mL) 121.17 ± 59.76, and D-dimer 0.61 ± 0.31. The CA-125 level increase in ovarian cancer patients it indication as a tumor marker.

Keywords: Ovarian cancer, CA-125, transvaginal ultrasound, prolactin level, CA19.9


How to Cite

MAZHAR, M. W., SAIF, S., RAZA, A., TAJ, A., WARIS, S., MANAN, A., IRFAN, M., TAHIR, H., & MAZHAR, F. (2021). PREVELANCE OF OVARIAN CANCER AND ITS CORELATION WITH AGE IN PAKISTAN. Asian Journal of Advances in Medical Science, 3(1), 462–466. Retrieved from https://mbimph.com/index.php/AJOAIMS/article/view/2697

Downloads

Download data is not yet available.

References

Shimosato Y, Mukai K, Matsuno Y. Tumors of the mediastinum. Amer Registry of Pathology; 2010.

Williams TI, et al. Epithelial ovarian cancer: disease etiology, treatment, detection, and investigational gene, metabolite, and protein biomarkers. Journal of Proteome Research. 2007;6(8):2936-2962.

Melikechi N, et al. Age-specific discrimination of blood plasma samples of healthy and ovarian cancer prone mice using laser-induced breakdown spectroscopy. Spectrochimica Acta Part B: Atomic Spectroscopy. 2016;123: 33-41.

Jayson GC, et al. Ovarian cancer. The Lancet. 2014;384(9951):1376-1388.

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209-249.

Xing F, Wang S, Zhou J. The expression of microRNA-598 inhibits ovarian cancer cell proliferation and metastasis by targeting URI. Molecular Therapy-Oncolytics. 2019;12: 9-15.

Mazhar MW. Breast cancer. Cancer Therapy & Oncology International Journal. 2021; 18(4).

Andrews L, Mutch DG. Hereditary ovarian cancer and risk reduction. Best Practice & Research Clinical Obstetrics & Gynaecology. 2017;41:31-48.

Olsen CM, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer. 2013;20(2):251-262.

Allen PL. Prospective study of symptoms of ovarian cancer in postmenopausal women. UCL (University College London); 2010.

Katzke VA, Kaaks R, Kühn T. Lifestyle and cancer risk. The Cancer Journal. 2015;21(2): 104-110.

Omoyajowo KO, et al. Awareness of toxicological impact and risk of using talcum powder as a factor for ovarian cancer among women in three metropolitan cities of Southwestern States of Nigeria; 2021.

Modugno F, et al. Breastfeeding factors and risk of epithelial ovarian cancer. Gynecologic Oncology. 2019;153(1):116-122.